FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a diarylthiohydantoin compound of formula (I), where R1, T, rings A and B are defined in the claims, as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition containing the compound, and to its use in the treatment of cellular proliferative disease mediated by androgens.
EFFECT: compound of the present application has a good androgen receptor antagonistic effect and excellent antitumor effect.
20 cl, 7 tbl, 80 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ERBB/BTK INHIBITORS | 2019 |
|
RU2764069C1 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | 2017 |
|
RU2756270C2 |
| TLR7/8 ANTAGONISTS AND THEIR APPLICATION | 2017 |
|
RU2758686C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | 2017 |
|
RU2716502C2 |
| DERIVATIVES OF 7-OXO-1,6-DIAZABICYCLO[3.2.1]OCT-3-ENE, USEFUL FOR BACTERIAL INFECTIONS TREATMENT | 2013 |
|
RU2645678C2 |
| NEW 3-INDOLE SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF APPLICATION | 2016 |
|
RU2672252C1 |
| PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
| HETEROCYCLIC COMPOUND, INTERMEDIATE COMPOUND, A METHOD OF ITS PRODUCTION AND ITS USE | 2019 |
|
RU2800153C2 |
